EFIL BioScience
Developer of therapeutics targeting metabolic diseases using ACAT inhibition as a mechanism to regulate adipogenesis, lipogenesis, and appetite. Focus areas include animal and human obesity, Prader-Willi syndrome, and localized fat disorders. Maintains a development pipeline, patent portfolio, and engagement with scientific, clinical, and strategy advisory boards. Holds a U.S. FDA orphan drug designation.
Industries
Biotechnology
Medical
Pharmaceutical
Biotechnology Research
Nr. of Employees
small (1-50)
EFIL BioScience
Products
ACAT inhibitor treatments
Innovative ACAT inhibitor treatments targeting metabolic diseases and obesity where traditional therapies fall short.
ACAT inhibitor treatments
Innovative ACAT inhibitor treatments targeting metabolic diseases and obesity where traditional therapies fall short.
Expertise Areas
- Metabolic disorder therapeutics
- Obesity therapeutics (human and animal)
- Prader-Willi syndrome research
- Drug discovery and preclinical development
Key Technologies
- ACAT inhibition
- Adipogenesis and lipogenesis assays
- Preclinical animal models for metabolic disease
- Mechanism-of-action pharmacology studies
News & Updates
Received orphan drug designation from the U.S. Food and Drug Administration.
Received orphan drug designation from the U.S. Food and Drug Administration.